Free Trial

Neuronetics Q4 2022 Earnings Report

Neuronetics logo
$2.46 +0.18 (+7.89%)
As of 01/17/2025 04:00 PM Eastern

Neuronetics EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.43
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Neuronetics Revenue Results

Actual Revenue
$18.20 million
Expected Revenue
$16.58 million
Beat/Miss
Beat by +$1.62 million
YoY Revenue Growth
N/A

Neuronetics Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Neuronetics Earnings Headlines

Stunning Trump Exec Order Leaked
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)...
Neuronetics sees FY25 revenue $145M-$155M
See More Neuronetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuronetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuronetics and other key companies, straight to your email.

About Neuronetics

Neuronetics (NASDAQ:STIM), a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

View Neuronetics Profile

More Earnings Resources from MarketBeat